{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:54:48Z","timestamp":1792364088200,"version":"4.4.0"},"reference-count":180,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"crossref","award":["ZIA AR041203"],"award-info":[{"award-number":["ZIA AR041203"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nmd.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:26:13Z","timestamp":1572002773000},"page":"70-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":303,"title":["239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018"],"prefix":"10.1016","volume":"30","author":[{"given":"Andrew L.","family":"Mammen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan De","family":"Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Casciola-Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Gitiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"E. Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Selva-O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2019.10.005_bib0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.10.005_bib0002","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0003","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.10.005_bib0005","first-page":"40","article-title":"Clinical and serological characterisation of the anti-MJ antibody in childhood myositis","author":"Oddis","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0006","first-page":"56","article-title":"Sera with autoantibodies to the MJ antigen react with NXP2","author":"Targoff","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0007","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0008","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein nxp-2 or transcription intermediary factor 1 gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0009","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0011","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0012","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3899\/jrheum.141443","article-title":"The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis","volume":"42","author":"Pinal-Fernandez","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0180","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.10.005_bib0013","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20170779","article-title":"Trim33 mediates the proinflammatory function of Th17 cells","volume":"215","author":"Tanaka","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2019.10.005_bib0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0017","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","article-title":"The association between mi-2 antibodies and dermatomyositis","volume":"28","author":"Targoff","year":"1985","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nmd.2019.10.005_bib0018","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0019","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.nmd.2019.10.005_bib0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/BOR.0000000000000548","article-title":"New insights in myositis-specific autoantibodies","volume":"30","author":"Ghirardello","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0022","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jdermsci.2005.09.004","article-title":"Prevalence and clinical characteristics of anti-MI-2 antibodies in japanese patients with dermatomyositis","volume":"40","author":"Komura","year":"2005","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.nmd.2019.10.005_bib0023","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0024","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.23012","article-title":"International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials","volume":"57","author":"Wedderburn","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2013-203396","article-title":"Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease","volume":"74","author":"Varsani","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-MI-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nmd.2019.10.005_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.nmd.2019.10.005_bib0028","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis","volume":"56","author":"Betteridge","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0029","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort","volume":"13","author":"Bodoki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2019.10.005_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","article-title":"Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort","volume":"72","author":"Fujimoto","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0031","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/rheumatology\/kev247","article-title":"High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis","volume":"54","author":"Muro","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0032","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2019.10.005_bib0033","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12026-018-9006-7","article-title":"Antibodies to small ubiquitin-like modifier activating enzyme are associated with a diagnosis of dermatomyositis: results from an unselected cohort","volume":"66","author":"Peterson","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.nmd.2019.10.005_bib0034","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/bjd.17026","article-title":"Diffuse erythema with 'angel wings' sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis","volume":"179","author":"Inoue","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0035","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nmd.2019.10.005_bib0036","first-page":"891","article-title":"Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0037","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","article-title":"Splicing variant of wdfy4 augments mda5 signalling and the risk of clinically amyopathic dermatomyositis","volume":"77","author":"Kochi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0038","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0039","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0040","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis","volume":"56","author":"Abe","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0041","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.170165","article-title":"HLA-DRB1 alleles as genetic risk factors for the development of anti-mda5 antibodies in patients with dermatomyositis","volume":"44","author":"Chen","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0042","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2019.10.005_bib0043","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0044","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0046","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/03009742.2017.1334814","article-title":"Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review","volume":"47","author":"Hoa","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0047","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0048","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0049","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","article-title":"A balancing act: MDA5 in antiviral immunity and autoinflammation","volume":"27","author":"Dias Junior","year":"2019","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0050","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nmd.2019.10.005_bib0051","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0052","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0053","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0054","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-mda5 antibody is associated with a\/sip and decreased t cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nmd.2019.10.005_bib0055","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2169\/internalmedicine.55.5774","article-title":"Radiological and pathological correlation in anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive perilobular opacities and diffuse alveolar damage","volume":"55","author":"Chino","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0056","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0057","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.nmd.2019.10.005_bib0058","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.nmd.2013.07.007","article-title":"193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November\u20132 December 2012, Naarden, the Netherlands","volume":"23","author":"De Bleecker","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.10.005_bib0059","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies part ii 28\u201330 march 2014, Naarden, the Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.10.005_bib0060","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008005","article-title":"Idiopathic inflammatory myopathy: interrater variability in muscle biopsy reading","author":"Olivier","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.10.005_bib0061","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0062","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MXA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.10.005_bib0063","article-title":"Diagnostic potential of sarcoplasmic MXA expression in subsets of dermatomyositis","author":"Uruha","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0064","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12551","article-title":"Absence of sarcoplasmic myxovirus resistance protein a (MXA) expression in antisynthetase syndrome in a cohort of 194 cases","author":"Inoue","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nmd.2019.10.005_bib0066","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-JO-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain: J Neurol."},{"key":"10.1016\/j.nmd.2019.10.005_bib0067","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.10.005_bib0068","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2230.2009.03216.x","article-title":"Defining cancer risk in dermatomyositis. Part I","volume":"34","author":"Madan","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0069","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andras","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11926-011-0169-7","article-title":"Malignancy in myositis","volume":"13","author":"Zahr","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.nmd.2019.10.005_bib0071","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1gamma (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0072","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000000683","article-title":"Anti-SAE antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature","author":"Matsuo","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0073","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.nmd.2019.10.005_bib0074","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0076","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0077","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2019.10.005_bib0078","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0079","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.170544","article-title":"Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0081","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nmd.2019.10.005_bib0082","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andr\u00e1s","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0083","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0084","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2340\/00015555-3091","article-title":"Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis","volume":"99","author":"Best","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.onc.1202655","article-title":"TIF1gamma, a novel member of the transcriptional intermediary factor 1 family","volume":"18","author":"Venturini","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.nmd.2019.10.005_bib0086","doi-asserted-by":"crossref","DOI":"10.1002\/art.40895","article-title":"The IGG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis","author":"Aussy","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0087","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.38137","article-title":"Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0088","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0089","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1136\/annrheumdis-2015-207762","article-title":"Gene copy-number variations (CNVS) of complement c4 and c4a deficiency in genetic risk and pathogenesis of juvenile dermatomyositis","volume":"75","author":"Lintner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in caucasians with myositis identifies significant associations with autoantibody subgroups","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0091","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","article-title":"IFN-beta-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis","volume":"134","author":"Meyer","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0092","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0093","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/path.4346","article-title":"Altered RIG-I\/DDX58-mediated innate immunity in dermatomyositis","volume":"233","author":"Suarez-Calvet","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0094","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-017-1383-0","article-title":"RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis","volume":"19","author":"Suarez-Calvet","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2019.10.005_bib0095","doi-asserted-by":"crossref","first-page":"e65362","DOI":"10.1371\/journal.pone.0065362","article-title":"Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15","volume":"8","author":"Franzi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2019.10.005_bib0096","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"Jak inhibitor improves type i interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2019.10.005_bib0097","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated sting in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0098","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/art.40328","article-title":"Myogenic progenitor cells exhibit type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis","volume":"70","author":"Gitiaux","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0099","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/nan.12243","article-title":"Expanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations","volume":"41","author":"Allenbach","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0100","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1038\/s41598-017-09309-8","article-title":"Hypoxia triggers IFN-I production in muscle: implications in dermatomyositis","volume":"7","author":"De Luna","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2019.10.005_bib0101","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0889-857X(02)00026-1","article-title":"Animal models of myositis","volume":"28","author":"Nagaraju","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.nmd.2019.10.005_bib0102","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2353\/ajpath.2009.080422","article-title":"Role of regulatory t cells in a new mouse model of experimental autoimmune myositis","volume":"174","author":"Allenbach","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0103","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.22521","article-title":"A new murine model to define the critical pathologic and therapeutic mediators of polymyositis","volume":"56","author":"Sugihara","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","article-title":"Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation","volume":"29","author":"Katsumata","year":"2007","journal-title":"J Autoimmun."},{"key":"10.1016\/j.nmd.2019.10.005_bib0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IGG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0106","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","article-title":"Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis","volume":"31","author":"Wenzel","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0107","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2019.10.005_bib0108","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/rheumatology\/keq261","volume":"50","author":"Martin","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0109","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/ar4198","article-title":"Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?","volume":"15","author":"Tansley","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2019.10.005_bib0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2019.10.005_bib0111","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0112","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in caucasians with myositis identifies significant associations with autoantibody subgroups","author":"Rothwell","year":"2019","journal-title":"Annals Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0113","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12528","article-title":"Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features","author":"Yasin","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0114","article-title":"Expression of myxovirus-resistance protein a: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","author":"Soponkanaporn","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0115","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3389\/fimmu.2018.02951","article-title":"Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools","volume":"9","author":"Wienke","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0116","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0117","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajmg.a.36887","article-title":"Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1","volume":"167A","author":"Crow","year":"2015","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.nmd.2019.10.005_bib0118","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0119","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0121","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2019.10.005_bib0122","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0123","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0124","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Muscle Study","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0126","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","article-title":"Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis","volume":"77","author":"Aggarwal","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0127","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0128","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.23340","article-title":"Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.23313","article-title":"Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0131","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM","volume":"132","author":"Goreshi","year":"2012","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0132","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaad.2019.01.028","article-title":"Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis","volume":"80","author":"Gaffney","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0133","article-title":"Evaluating important change ion cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","author":"Ahmed","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0134","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0135","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0136","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the cutaneous dermatomyositis disease area and severity index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0137","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/bjd.15596","article-title":"Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists","volume":"177","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0138","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2018-eular.3531","article-title":"Phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis","volume":"77","author":"Werth","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0139","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0140","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0141","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0142","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0143","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211401","volume":"76","author":"Rider","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0144","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0145","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/art.21715","article-title":"Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis","volume":"55","author":"Alexanderson","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0146","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.26307","article-title":"Muscle endurance deficits in myositis patients despite normal manual muscle testing scores","volume":"59","author":"Amici","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.10.005_bib0147","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/JND-180358","article-title":"Responsiveness to change of 5-point MRC scale, endurance and functional evaluation for assessing myositis in daily clinical practice","volume":"6","author":"Landon-Cardinal","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0148","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3899\/jrheum.161183","article-title":"Muscle strength and muscle endurance during the first year of treatment of polymyositis and dermatomyositis: a prospective study","volume":"45","author":"Alexanderson","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0149","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.23491","article-title":"Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care","volume":"70","author":"Varnier","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0151","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3899\/jrheum.150270","article-title":"Proposal for a candidate core set of fitness and strength tests for patients with childhood or adult idiopathic inflammatory myopathies","volume":"43","author":"van der Stap","year":"2016","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.nmd.2019.10.005_bib0152","first-page":"S118","volume":"63 Suppl","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0153","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194531","article-title":"Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: an intra- and interrater reliability and validity study","volume":"13","author":"Baschung Pfister","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2019.10.005_bib0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000004061","article-title":"Physical activity monitoring: a promising outcome measure in idiopathic inflammatory myopathies","volume":"89","author":"Bachasson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.10.005_bib0156","doi-asserted-by":"crossref","first-page":"e1298","DOI":"10.1259\/bjr\/14063641","article-title":"Skeletal muscle disease: patterns of MRI appearances","volume":"85","author":"Theodorou","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0157","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000850","article-title":"MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis","volume":"5","author":"Ukichi","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.nmd.2019.10.005_bib0158","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0000000000000435","article-title":"MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies","volume":"29","author":"Kubinova","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0159","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00281-015-0543-z","article-title":"Cutaneous dermatomyositis in the era of biologicals","volume":"38","author":"Wright","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/1529-0131(200102)44:2<389::AID-ANR58>3.0.CO;2-R","article-title":"The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen","volume":"44","author":"Casciola-Rosen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0161","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2019.10.005_bib0162","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEP-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.10.005_bib0163","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.autrev.2009.01.013","article-title":"Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory","volume":"8","author":"Bossuyt","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2019.10.005_bib0164","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0166","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0167","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0168","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.14801","article-title":"Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis","volume":"176","author":"Ang","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0169","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18133","article-title":"Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice","author":"Gandiga","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0170","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti JO-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2019.10.005_bib0171","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0172","first-page":"159","article-title":"Polymyositis-dermatomyositis: diagnostic and prognostic significance of muscle alkaline phosphatase","volume":"101","author":"Cros","year":"1980","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0173","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","article-title":"Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the JO-1 antibody system","volume":"23","author":"Nishikai","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.10.005_bib0174","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-TRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Q J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0175","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2019.10.005_bib0176","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0177","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.10.005_bib0178","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.10.005_bib0179","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619311617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619311617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:20Z","timestamp":1760774960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896619311617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":180,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0960896619311617"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.10.005","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}